Proactive Investors - Run By Investors For Investors

Redx Pharma moves higher as it reveals more “potent efficacy data” for leukaemia drug

The positive data keeps Redx on track to lodge a clinical trial application and investigational new drug application for RXC005 later this year
test tubes in a laboratory
RXC005 is being designed for use in people with chronic lymphocytic leukaemia

Shares in Redx Pharma Plc (LON:REDX) jumped more than 7% on Monday morning after it confirmed it will make a clinical trial application (CTA) and investigational new drug (IND) application for its RXC005 leukaemia treatment later this year.

The confirmation comes after the drug researcher and developer presented further “potent efficacy data” at the prestigious 17th International Workshop of Chronic Lymphocytic Leukaemia (iwCLL) in New York over the weekend.

READ MORE: Cash influx will help Redx develop promising pre-clinical drug candidates

RXC005 – a Bruton’s tyrosine kinase inhibitor or BTK for short – is being designed for use in people with chronic lymphocytic leukaemia.

Importantly, it is also targeting those who have built up a resistance to the current best-in-class treatment, Imbruvica (often referred to as Ibrutinib).

The drug is being developed as a second-generation of compound which has fewer side-effects than the market leader.

RXC005 demonstrates “significant efficacy”

The data presented showed that the drug successfully inhibits wild-type BTK, mutant BTK as well as primary CLL cells.

RXC005 was also shown to be highly selective and exhibits improved target specificity against other Tec and Src kinase family members, Redx added.

“The data presented is further validation of RXC005's potential to target both wild-type and mutant BTK, an important emerging resistance mechanism in patients with CLL progression following ibrutinib treatment,” said chief scientific officer Richard Amer.

“With good target engagement demonstrated in the PK/PD studies and efficacy in mouse-models, we look forward to filing an IND/CTA in late 2017 to take RXC005 into the clinic.”

Chief executive Neil Murray added: “We are delighted to have presented further potent efficacy data for one of our lead development candidates, RXC005, at the prestigious iwCLL event in front of our peers and contemporaries.”

Shares were up 7.5% to 32.5p shortly before midday.

--Updates for share price--

View full REDX profile View Profile

Redx Pharma Plc Timeline

CN Research
April 06 2017

Related Articles

picture of an affimer
April 03 2017
Avacta has developed an innovative protein-scaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets
January 25 2017
The company's update reveals a company in rude health
Vaxil at the vanguard of immuno-oncology
January 06 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use